Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024

August 2017 | 120 pages | ID: FBFED4B91C0EN
DPI Research

Abstracts

United States flu vaccine market is expected to reach nearly US$ 3 Billion by 2024. Growth in US flu vaccine market can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against flu vaccine and introduction of quadrivalent flu vaccine.

Long–term Growth Projection and Development:

• Sanofi to Acquire Protein Sciences Corporation
• It is likely that more than 185 Million persons being vaccinated with flu vaccines in 2024.
• Nearly 160 Million doses of flu vaccines have shipped to US for the 2017-2018 flu season
• It is projected that GSK flu vaccine sales value will reach around US$ 1.5 Billion by 2024
• BiondVax reports positive phase 2b clinical trial results for its universal flu vaccine

“Flu Vaccine Market Outlook 2024: United States Opportunity and Demand Analysis, Market Forecast 2017-2024” provides a deep and thorough evaluation of the United States flu vaccine market. The report provides an in–depth analysis of the flu vaccination pattern in both Children and Adults in the United States. It also provides essential insights into flu vaccine production, price, consumption, supply, distribution, demand and specification. It also covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials and promising flu vaccines in the clinical development. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.

The report concludes with the profiles of major players in the US flu vaccine market such as Sanofi Pasteur, GSK and Seqirus. The major market players are evaluated on various parameters such as company overview, product outlook, latest development & trends and sales analysis of flu vaccine market from 2011 to 2022. The report also entails major drivers and inhibitors in the US flu vaccine market.

Key Topics Covered in the Report

• Market Overview: United States Flu Vaccine Market (2010 - 2024)
• United States Number of Persons Vaccinated with Flu Vaccine (2010 - 2024)
• United States Flu Vaccine Production, Price, Consumption, Supply, Distribution, Demand and Specification
• Reimbursement & Regulatory System in the US Flu Vaccine Market
• Mergers, Acquisitions, Key Agreements & Collaborations
• Promising Flu Vaccine in Clinical Development
• Flu Vaccine Clinical Trial Insights by Phase, Company & Country
• Key Drivers and Inhibitors of the US Flu Vaccine Market
• Key Companies Analysis

Major Flu Vaccines Covered Under This Report Are:

• Fluzone High–Dose
• Fluzone Quadrivalent
• Intradermal (ID) Trivalent
• Vaxigrip
• Fluarix Quadrivalent
• Flulaval Quadrivalent
• Flucelvax Quadrivalent
• Afluria Quadrivalent
• Agrippal
• Fluad
• Fluvirin
• Fluvax

Key Companies Covered in This Report:

• Seqirus
• Sanofi Pasteur
• GlaxoSmithKline(GSK)

Contents

1. EXECUTIVE SUMMARY

2. MARKET OVERVIEW: UNITED STATES FLU VACCINE MARKET (2010 - 2024)

3. UNITED STATES NUMBER OF PERSONS VACCINATED WITH FLU VACCINE (2010 - 2024)

3.1 Number of Children Vaccinated
3.2 Number of Adults Vaccinated

4. KEY DRIVERS AND INHIBITORS OF THE UNITED STATES FLU VACCINE MARKET

4.1 Market Drivers
4.2 Market Inhibitors

5. UNITED STATES FLU VACCINE PRODUCTION, PRICE, CONSUMPTION, SUPPLY, DISTRIBUTION, DEMAND AND SPECIFICATION

5.1 Flu Vaccine Price Trends
  5.1.1 Pediatric Flu Vaccine Price Trends
  5.1.2 Adult Flu Vaccine Price Trends
5.2 United States Flu Vaccine Production, Supply, and Allocation (By Companies)
5.3 United States Flu Vaccine Distribution & Demand
5.4 Flu Vaccine Effectiveness
5.5 Managing Flu with Rapid Diagnostic Testing
5.6 Distribution Method of Flu Vaccination

6. UNITED STATES FLU VACCINE MARKET – REIMBURSEMENT & REGULATORY SYSTEM

6.1 Reimbursement System
6.2 Regulation System

7. MARKET DYNAMICS – MERGERS, ACQUISITIONS, KEY AGREEMENTS & COLLABORATIONS

7.1 Merger & Acquisitions
7.2 Collaboration Deal
7.3 Licensing, Exclusive & Distribution Agreement Deal
  7.3.1 Licensing Agreement
  7.3.2 Exclusive Agreement
  7.3.3 Distribution Agreement

8. FLU VACCINE – PROMISING VACCINE IN CLINICAL DEVELOPMENT

8.1 Quadrivalent Seasonal Influenza VLP Vaccine
8.2 VN –
8.3 Seasonal Influenza VLP Vaccine
8.4 M–001

9. FLU VACCINE – CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY & COUNTRY

9.1 Year 2017
9.2 Year 2016

10. KEY COMPANIES ANALYSIS

10.1 Sanofi Pasteur
  10.1.1 Business Overview
  10.1.2 Flu Vaccine Outlook
    10.1.2.1 Fluzone High–Dose Vaccine
    10.1.2.2 Fluzone Quadrivalent Vaccine
    10.1.2.3 Intradermal (ID) Trivalent Flu Vaccine
    10.1.2.4 Vaxigrip Vaccine
  10.1.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024)
  10.1.4 Flu Vaccine – Latest Development and Trends
10.2 GlaxoSmithKline (GSK)
  10.2.1 Business Overview
  10.2.2 Flu Vaccine Outlook
    10.2.2.1 Fluarix Quadrivalent
    10.2.2.2 Flulaval Quadrivalent
  10.2.3 Flu Vaccine Sales Analysis & Forecast (2011 - 2024)
  10.2.4 Flu Vaccine – Latest Development & Trends
10.3 Seqirus (CSL Limited)
  10.3.1 Business Overview
  10.3.2 Flu Vaccine Outlook
    10.3.2.1 Flucelvax Quadrivalent
    10.3.2.2 Afluria Quadrivalent
    10.3.2.3 Agrippal
    10.3.2.4 Fluad
    10.3.2.5 Fluvirin
    10.3.2.6 Fluvax
  10.3.3 Flu Vaccine – Latest Development & Trends

List Of Tables

LIST OF TABLES

Table 5–2: United States – Pediatric Flu Vaccine Price, 2017 – 2018
Table 5–3: United States – Adult Flu Vaccine Price, 2017 – 2018
Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation
Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017
Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016
Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015
Table 5–8: Adjusted Vaccine Effectiveness Estimates for Flu Seasons, 2005 – 2016
Table 5–9: Influenza Virus Testing Methods
Table 5–10: Distribution of Flu Vaccination
Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 7–1: Flu Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2017
Table 7–2: Flu Vaccine Market – Collaborations Deal,2007 – 2017
Table 7–3: Flu Vaccine Market – Licensing Agreement,2007 – 2016
Table 7–4: Flu Vaccine Market – Exclusive Agreement,2009 – 2016
Table 7–5: Flu Vaccine Market – Distribution Agreement,2005 – 2016

List Of Figures

LIST OF FIGURES

Figure 2 1: United States – Flu Vaccine Market (Million US$),2010 – 2016
Figure 2 2: United States – Forecast for Flu Vaccine Market (Million US$),2017 – 2024
Figure 3 1: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2016
Figure 3 2: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2017 – 2024
Figure 3 3: United States – Number of Children Vaccinated(Thousand),2010 – 2016
Figure 3 4: United States – Forecast for Number of Children Vaccinated(Thousand),2017 – 2024
Figure 3 5: United States – Number of Adults Vaccinated(Thousand),2010 – 2016
Figure 3 6: United States – Forecast for Number of Adults Vaccinated(Thousand),2017 – 2024
Figure 5 1: United States – Flu Vaccine Doses Distributed, By Season(Million),2010 – 2017
Figure 10 1: Sanofi Pasteur – Flu Vaccine Net Sales (Million US$),2011 – 2016
Figure 10 2: Sanofi Pasteur – Forecast for Flu Vaccine Net Sales (Million US$),2017 – 2024
Figure 10 3: GSK – Flu Vaccine Net Sales (Million US$),2011 – 2016
Figure 10 4: GSK – Forecast for Flu Vaccine Net Sales (Million US$),2017 – 2024